Back to results
US 8,785,454 B2Granted
Heterocyclic compounds and uses thereof
AssigneeIntellikine LLC
InventorsPingda Ren, Yi Liu, Liansheng Li, Troy Edward Wilson
Life of this patent
Estimating the term…
Abstract
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
Claims39
A compound of Formula I-A:
- or a pharmaceutically acceptable salt thereof, wherein
- W1 is N or CR5, W2 is N or CR6, W3 is N or CR7, W4 is N or CR8, wherein no more than two N atoms are adjacent;
- R1 is -(L)n—R1;
- L is —S—, —N(R2)—, —C(R3)2—, or —O—;
- n is 0 or 1;
- R1′ is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
- R4, R5, R6, R7 and R8 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
- X is absent or is —(CH(R10)) z— and z is an integer of 1, 2, 3, or 4;
- Y is absent, —O—, —S—, —S(═O)—, —S(═O)2—, —N(R9)—, —C(═O)—, —N(R9)—C(═O)—, —N(R9)—C(═O)NH—,)—N(R9)C(R102—, or —C(═O)—(CHR10)z—;
- each instance of R2 and R9 is independently hydrogen, C1-C10alkyl, C3-C7cycloalkyl, heterocycloalkyl, C2-C10heteroalkyl, aryl, or heteroaryl;
- each instance of R3 and R10 is independently hydrogen, alkyl, aryl, heteroaryl, or halo;
- and
- Wd is
- wherein each instance of Ra is independently hydrogen or alkyl;
- R11 is H, alkyl, halo, amino, amido, hydroxyl, or alkoxy, and
- R12 is H, alkyl, cyano, alkynyl, alkenyl, halo, aryl, heteroaryl, heterocyloalkyl, cycloalkyl, amino, carboxylic acid, acyloxy, alkoxycarbonyl, or amino.
13 more elements
A compound of Formula I-B:
- or a pharmaceutically acceptable salt thereof, wherein
- W1 is N or CR5, W2 is N or CR6, W3 is N or CR7, W4 is N or CR8, wherein no more than two N atoms are adjacent;
- R1 is —(L)n—R1′;
- L is —S—, —N(R2)—, —C(R3)2—, or —O—;
- n is 0or 1;
- R1′ is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
- R5, R6, R7 and R8 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
- X is absent or is —(CH(R10))z— and z is an integer of 1, 2, 3, or 4;
- Y is absent, —O—, —S—, —S(═O)—, —S(═O)2—, —N(R9)—, —C(═O)—, —N(R9)—C(═O)—, —N(R9)—C(═O)NH—,—N(R9)C(R102—,or —C(═O)—(CHR10)z—;
- each instance of R2 and R9 is independently hydrogen, C1-C10alkyl, C3-C7cycloalkyl, heterocycloalkyl, C2-C10heteroalkyl, aryl, or heteroaryl;
- each instance of R3 and R10 is independently hydrogen, alkyl, aryl, heteroaryl or halo;
- and
- Wd is
- wherein each instance of Ra is independently hydrogen or alkyl;
- R11 is H, alkyl, halo, amino, amido, hydroxyl, or alkoxy, and
- R12 is H, alkyl, cyano, alkynyl, alkenyl , halo, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, amino, carboxylic acid, acyloxy, alkoxycarbonyl, or amino.
13 more elements
Dependencies are inferred from the claim text.